Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Sun Pharma ANZ Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (452)
Cancellation by sponsor (155)
Prescription medicine registration (29)
Section 14, TGO91 consent (5)
Australian public assessment report (AusPar) (4)
Prescription medicine decision summary (1)

Date

2026 (15)
2025 (40)
2024 (47)
2023 (36)
2022 (54)
2021 (42)
2020 (25)
2019 (26)
2018 (50)
2017 (18)
2016 (35)
2015 (20)
2014 (10)
2013 (22)
2012 (62)
2011 (92)
2010 (14)
2009 (13)
2007 (12)
2006 (10)
2005 (3)

Search

Sponsor content

646 result(s) found, displaying 71 to 80

ACICLOVIR RBX aciclovir 400mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

4 October 2024

Cancellation by sponsor

Requested by Sun Pharma ANZ Pty Ltd
Zoledronic Acid SUN zoledronic acid 5 mg / 100 mL injection solution vial Cancelled under Section 30(1)(c) of the Act

27 September 2024

Cancellation by sponsor

Requested by Sun Pharma ANZ Pty Ltd
ACICLOVIR GH aciclovir 800mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 September 2024

Cancellation by sponsor

Requested by Sun Pharma ANZ Pty Ltd
ACICLOVIR GH aciclovir 400mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 September 2024

Cancellation by sponsor

Requested by Sun Pharma ANZ Pty Ltd
AusPAR: Winlevi

21 August 2024

Australian public assessment report (AusPar)

Winlevi (clascoterone) has been approved to treat acne vulgaris in patients 12 years of age or older.
AusPAR: Yonsa Mpred

8 August 2024

Australian public assessment report (AusPar)

Yonsa Mpred (abiraterone acetate + methylprednisolone) has been approved for the treatment of metastatic castration resistant prostate cancer and metastatic hormone sensitive prostate cancer.
VIVALA ganirelix (as acetate) 250 microgram/0.5 mL solution for injection prefilled syringe (409179)

24 August 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for VIVALA ganirelix (as acetate) 250 microgram/0.5 mL solution for injection prefilled syringe.
CEQUA SUN ciclosporin 900 microgram/mL eye drops ampoule (408814)

7 August 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for CEQUA SUN ciclosporin 900 microgram/mL eye drops ampoule.
Gemcitabine SUN gemcitabine hydrochloride 2000mg/200mL solution for infusion bag Cancelled under Section 30(1)(c) of the Act

9 July 2024

Cancellation by sponsor

Requested by Sun Pharma ANZ Pty Ltd
Gemcitabine SUN gemcitabine hydrochloride 1900mg/190mL solution for infusion bag Cancelled under Section 30(1)(c) of the Act

9 July 2024

Cancellation by sponsor

Requested by Sun Pharma ANZ Pty Ltd

Pages

First page
Previous page
…
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Page 12
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.